Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$965K
Filings
27
Firms Hired
3
Active Period
2021–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
VALID Act (HR 4128/S 2209); General Issues related to data privacy and security
Client expense: $90,000 · Firm income: —
Matched citations: HR 4128
Veteran Federal Procurement Entrepreneurship Training Program Act
2023 · first_quarter · Firm: TEMPUS LABS INC
VALID Act (HR 4128/S 2209); General Issues related to data privacy and security
Client expense: $90,000 · Firm income: —
Matched citations: S 2209
Access and reimbursement to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing;The VALID Act (HR 4128 and S 2209). Increasing overall access to and diversity of clinical trials. Advancing acceptance of Real World Data and Real World Evidence.
Client expense: $80,000 · Firm income: —
Matched citations: HR 4128
VALID Act (HR 4128/S.2209); Issues related to proposals on reauthorization of the FDA drug and device user fee programs (S.4348/H.R.7667), (H.R. 6833); Issues related to data privacy and security House legislation (H.R. 8152).
Client expense: $80,000 · Firm income: —
Matched citations: HR 4128
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · fourth_quarter · Firm: TEMPUS LABS INC
VALID Act (HR 4128/S.2209); Issues related to proposals on reauthorization of the FDA drug and device user fee programs (S.4348/H.R.7667), (H.R. 6833); Issues related to data privacy and security House legislation (H.R. 8152).
Client expense: $80,000 · Firm income: —
Matched citations: H.R. 6833
Food and Drug Amendments of 2022
2022 · fourth_quarter · Firm: TEMPUS LABS INC
VALID Act (HR 4128/S.2209); Issues related to proposals on reauthorization of the FDA drug and device user fee programs (S.4348/H.R.7667), (H.R. 6833); Issues related to data privacy and security House legislation (H.R. 8152).
Client expense: $80,000 · Firm income: —
Matched citations: H.R.7667
American Data Privacy and Protection Act
2022 · fourth_quarter · Firm: TEMPUS LABS INC
VALID Act (HR 4128/S.2209); Issues related to proposals on reauthorization of the FDA drug and device user fee programs (S.4348/H.R.7667), (H.R. 6833); Issues related to data privacy and security House legislation (H.R. 8152).
Client expense: $80,000 · Firm income: —
Matched citations: H.R. 8152
American Data Privacy and Protection Act
2022 · fourth_quarter · Firm: TEMPUS LABS INC
Issues related to cancer diagnostic testing; Medicare coverage of molecular and advanced genomic testing tests; Precision medicine; Health care issues related to data privacy and security House legislation (H.R. 8152).
Client expense: $80,000 · Firm income: —
Matched citations: H.R. 8152
American Data Privacy and Protection Act
2022 · fourth_quarter · Firm: TEMPUS LABS INC
Issues related to cancer diagnostic testing; Medicare coverage of molecular and advanced genomic testing tests; Precision medicine; Health care issues related to data privacy and security House legislation (H.R. 8152).
Client expense: $80,000 · Firm income: —
Matched citations: H.R. 8152
Access and reimbursement to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing;The VALID Act (HR 4128 and S 2209). Increasing overall access to and diversity of clinical trials. Advancing acceptance of Real World Data and Real World Evidence.
Client expense: $80,000 · Firm income: —
Matched citations: S 2209
VALID Act (HR 4128/S.2209); Issues related to proposals on reauthorization of the FDA drug and device user fee programs (S.4348/H.R.7667), (H.R. 6833); Issues related to data privacy and security House legislation (H.R. 8152).
Client expense: $80,000 · Firm income: —
Matched citations: S.2209
VALID Act (HR 4128/S.2209); Issues related to proposals on reauthorization of the FDA drug and device user fee programs (S.4348/H.R.7667), (H.R. 6833); Issues related to data privacy and security House legislation (H.R. 8152).
Client expense: $80,000 · Firm income: —
Matched citations: S.4348
VALID Act (HR 4128/S.2209); General Issues related to data privacy and security.
Client expense: $90,000 · Firm income: —
Matched citations: HR 4128
VALID Act (HR 4128/S.2209); General Issues related to data privacy and security.
Client expense: $90,000 · Firm income: —
Matched citations: S.2209
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: TEMPUS LABS INC
VALID Act of 2021 (HR 4128/S.2209); Issues related to proposals on reauthorization of the FDA drug and device user fee programs within Omnibus Bill (H.R. 2617 ); Issues related to data privacy and security House legislation (H.R. 8152).
Client expense: $90,000 · Firm income: —
Matched citations: H.R. 2617
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: TEMPUS LABS INC
Access and reimbursement to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing; The VALID Act (HR 4128 and S 2209) and Omnibus legislation (H.R. 2617). Increasing overall access to and diversity of clinical trials. Advancing acceptance of Real World Data and Real World Evidence.
Client expense: $90,000 · Firm income: —
Matched citations: H.R. 2617
Access and reimbursement to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing; The VALID Act (HR 4128 and S 2209) and Omnibus legislation (H.R. 2617). Increasing overall access to and diversity of clinical trials. Advancing acceptance of Real World Data and Real World Evidence.
Client expense: $90,000 · Firm income: —
Matched citations: HR 4128
VALID Act of 2021 (HR 4128/S.2209); Issues related to proposals on reauthorization of the FDA drug and device user fee programs within Omnibus Bill (H.R. 2617 ); Issues related to data privacy and security House legislation (H.R. 8152).
Client expense: $90,000 · Firm income: —
Matched citations: HR 4128
American Data Privacy and Protection Act
2022 · fourth_quarter · Firm: TEMPUS LABS INC
Data Privacy(H.R. 8152).; Artificial Intelligence/Machine Learning in healthcare. Increasing multi-modal data in medical research and innovation. Advancing acceptance of Real World Data and Real World Evidence. Diversity of clinical trials.
Client expense: $90,000 · Firm income: —
Matched citations: H.R. 8152
American Data Privacy and Protection Act
2022 · fourth_quarter · Firm: TEMPUS LABS INC
VALID Act of 2021 (HR 4128/S.2209); Issues related to proposals on reauthorization of the FDA drug and device user fee programs within Omnibus Bill (H.R. 2617 ); Issues related to data privacy and security House legislation (H.R. 8152).
Client expense: $90,000 · Firm income: —
Matched citations: H.R. 8152
American Data Privacy and Protection Act
2022 · fourth_quarter · Firm: TEMPUS LABS INC
Issues related to cancer diagnostic testing; Medicare coverage of molecular and advanced genomic testing tests; Precision medicine; Health care issues related to data privacy and security House legislation (H.R. 8152).
Client expense: $90,000 · Firm income: —
Matched citations: H.R. 8152
VALID Act of 2021 (HR 4128/S.2209); Issues related to proposals on reauthorization of the FDA drug and device user fee programs within Omnibus Bill (H.R. 2617 ); Issues related to data privacy and security House legislation (H.R. 8152).
Client expense: $90,000 · Firm income: —
Matched citations: S.2209
Access and reimbursement to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing; The VALID Act (HR 4128 and S 2209) and Omnibus legislation (H.R. 2617). Increasing overall access to and diversity of clinical trials. Advancing acceptance of Real World Data and Real World Evidence.
Client expense: $90,000 · Firm income: —
Matched citations: S 2209
VALID Act of 2021 (HR 4128/S.2209); Issues related to proposals on reauthorization of the FDA drug and device user fee programs (S.4348/H.R. 7667), (H.R. 6833); Issues related to data privacy and security House legislation (H.R. 8152).
Client expense: $80,000 · Firm income: —
Matched citations: HR 4128
Access and reimbursement to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing; The VALID Act (HR 4128 and S 2209). Increasing overall access to and diversity of clinical trials. Advancing acceptance of Real World Data and Real World Evidence.
Client expense: $80,000 · Firm income: —
Matched citations: HR 4128
Source: Senate LDA